Besides codon 12, both codon 13 and 61 are also frequently mutated, like glycine to cysteine (G13C) and glutamine to histidine (Q61H).43 In NSCLC, studies have revealed that RAS pathway inhibitors, possibly unlike distinctively from those against other oncogenic pathways, could potentially amplify the immunogenicity of these tumors via a range of mechanisms, including reducing PD-L1 expression, promoting the synthesis of MHC-I molecules, altering the tumor microenvironment to facilitate T cell activity, and escalating the proportion of antitumor macrophages relative to pro-tumor macrophages. Here, CD274 is linked to neoplasm.